I B 567,568,570 In patients receiving DES for a non-ACS indication, clopidogrel 75 mg/d should be given for at least 12 mo if patients are not at high risk of bleeding. I B 208,212,571 In patients receiving BMS for a non-ACS indication, clopidogrel should be given for a minimum of 1 mo and ideally up to 12 mo (unless the patient is at increased risk of bleeding; then it should be given for a minimum of 2 wk). I B 572 Patients should be counseled on the importance of compliance with DAPT and that therapy should not be discontinued before discussion with their cardiologist. I C 208 PPIs should be used in patients with a history of prior GI bleeding who require DAPT. I C 794 If the risk of morbidity from bleeding outweighs the anticipated benefit afforded by a recommended duration of P2Y12 inhibitor therapy after stent implantation, earlier discontinuation (eg, 12 mo) of P2Y12 inhibitor therapy is reasonable. IIa C N/A Use of PPIs is reasonable in patients with an increased risk of GI bleeding (eg, advanced age, concomitant use of warfarin, steroids, NSAIDs, Helicobacter pylori infection) who require DAPT. IIa C 794 Continuation of clopidogrel, prasugrel, or ticagrelor beyond 12 mo may be considered in patients undergoing placement of DES. IIb C N/A Routine use of a PPI is not recommended for patients at low risk of GI bleeding, who have much less potential to benefit from prophylactic therapy. III: No Benefit C 794 Exercise testing For patients entering a formal cardiac rehabilitation program after PCI, treadmill exercise testing is reasonable. IIa C 567,568 Routine periodic stress testing of asymptomatic patients after PCI without specific clinical indications should not be performed. 